Background Although clozapine is effective for treatment-resistant schizophrenia (TRS), the
rate of clozapine prescription is still low. Whereas antipsychotic monotherapy is …

Aim This study aims to examine the real‐world effectiveness of education regarding clinical
guidelines for psychiatric disorders using 'the Effectiveness of guidelines for dissemination …

Study objectives To investigate the proportion of inpatients with schizophrenia and major
depressive disorder prescribed hypnotic medication, and the association between such …

Clozapine is the only approved antipsychotic for treatment-resistant schizophrenia (TRS).
Although a large body of evidence supports its efficacy and favorable risk-benefit ratio in …

Background Although several guidelines indicate that daily pharmacotherapy is an
important part of the treatment of schizophrenia and major depressive disorder, there are …

Purpose In the treatment guidelines for major depressive disorder (MDD), the recommended
treatment differs based on the severity. However, the type of treatment provided based on …

In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not
recommended. We investigated the characteristics of the use of anticholinergics in patients …

Background Recent pharmacoepidemiology data show an increase in the proportion of
patients receiving second-generation antipsychotic (SGA) monotherapy, but no studies have …

Aim We investigated the association of electroconvulsive therapy (ECT) with anxiolytic and
sleep medication use in patients with major depressive disorder (MDD) and schizophrenia …

Background Polypharmacy of additional psychotropics alongside the main treatment drug
(antipsychotics in schizophrenia and antidepressants in major depressive disorder) is …